S&P Global Ratings improved its rating of Main Line Health from ‘negative’ to ‘stable,’ writes John George for the Philadelphia Business Journal.
S&P cites the healthcare group’s improved fiscal performance. They affirmed an AA- rating which is considered investment grade, saying Main Line Health has a ‘strong capacity’ to meet financial obligations.
This new outlook follows a strong 2024 fiscal year for Main Line Health. They halved their operating loss from $125.3 million in 2023 to $61.1 million and operating revenue rose by 9 percent to $2.29 billion. Overall revenue reached nearly $2.4 billion.
The health group’s portfolio includes four acute care hospitals, outpatient centers, addiction treatment centers, and a research institute. They also co-own the Delaware Valley ACO with Jefferson Health and Humana.
Already into the 2025 fiscal year, Main Line Health reported an operating loss of $3.6 million in the first quarter. This is down from $27.8 million year-over-year. Revenue is up 9.5 percent.
CFO Leigh Ehrlich says the fiscal improvements stem from renegotiated payer contracts.
The health group is still hunting for a replacement for CEO Jack Lynch, who will retire in June.
Read more about the improvement of Main Line Health’s S&P Global Ratings in the Philadelphia Business Journal.
